Keyphrases
Multiple Sclerosis
100%
Relapsing-remitting multiple Sclerosis
36%
Multiple Sclerosis Treatment
35%
Myasthenia Gravis
29%
Immune Cells
22%
Healthy Controls
17%
Dysregulated
15%
MS Patients
15%
T Cells
13%
Susac Syndrome
12%
Israel
11%
Brain-derived Neurotrophic Factor
8%
Progressive multiple Sclerosis
8%
Bone Morphogenetic protein-2 (BMP-2)
8%
Demyelination
7%
Autoimmune Disease
7%
Interferon-α (IFN-α)
7%
CD4+ T Cells
7%
Vaccination
6%
Untreated Patients
6%
Acetylcholine Receptor (AChR)
6%
Ocular Myasthenia Gravis
6%
Ashkenazi
6%
Jewish Population
6%
Oligodendrogenesis
5%
CD40
5%
Gait
5%
Bone Morphogenic Protein
5%
Serum Levels
5%
Relapsing-remitting MS
5%
Cognitive Function
5%
Acetylcholine Receptor Antibody
5%
Randomized Controlled Trial
5%
Inflammation
5%
Ashkenazi Jews
5%
KIR4.1 Antibody
5%
Physical Activity
5%
Cyclophosphamide
5%
Disease Relapse
5%
6-minute Walk Test (6MWT)
5%
Frailty
5%
Immunology and Microbiology
Multiple Sclerosis
51%
Myasthenia gravis
20%
Relapsing Remitting Multiple Sclerosis
19%
T Cell
18%
Immunocompetent Cell
14%
Monospecific Antibody
9%
T-Helper Cell
9%
Vaccination Policy
8%
CD3 Antigen
6%
interferon
6%
Secondary Progressive Multiple Sclerosis
6%
Secretion (Process)
6%
Brain Derived Neurotrophic Factor
6%
Epitope
6%
Bone Morphogenetic Protein
6%
Tumor Necrosis Factor
5%
Autoimmune Disease
5%
Peripheral Blood Mononuclear Cell
5%
Neuromyelitis Optica
5%
Autoimmunity
5%
Cyclophosphamide
5%
Myelin Oligodendrocyte Glycoprotein
5%
Humoral Immunity
5%
Neuroscience
Multiple Sclerosis
68%
Relapsing Remitting Multiple Sclerosis
27%
Myasthenia gravis
20%
T Cell
16%
Interferon
12%
Brain-Derived Neurotrophic Factor
10%
Bone Morphogenetic Protein
9%
Oligodendrocyte
6%
CD4
6%
Sensorineural Hearing Loss
6%
Bone Morphogenetic Protein 2
5%
Randomized Controlled Trial
5%
Remyelinization
5%
Cognitive Function
5%
Human Leukocyte Antigen
5%
Myelin Oligodendrocyte Glycoprotein
5%
